Name
CRISPR Therapeutics
What We Do
CASGEVY? (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.
Website
Address
105 West First Street
South Boston, MA 02127
United States
South Boston, MA 02127
United States